ATE138100T1 - Fusionen von aids-verwandten polypeptiden - Google Patents

Fusionen von aids-verwandten polypeptiden

Info

Publication number
ATE138100T1
ATE138100T1 AT85309454T AT85309454T ATE138100T1 AT E138100 T1 ATE138100 T1 AT E138100T1 AT 85309454 T AT85309454 T AT 85309454T AT 85309454 T AT85309454 T AT 85309454T AT E138100 T1 ATE138100 T1 AT E138100T1
Authority
AT
Austria
Prior art keywords
aids
associated retrovirus
reverse transcriptase
diagnostic product
vaccine
Prior art date
Application number
AT85309454T
Other languages
English (en)
Inventor
Daniel Jeffrey Capon
Laurence Allan Lasky
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27103546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE138100(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE138100T1 publication Critical patent/ATE138100T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245Escherichia (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT85309454T 1984-12-24 1985-12-23 Fusionen von aids-verwandten polypeptiden ATE138100T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68527284A 1984-12-24 1984-12-24
US80506985A 1985-12-04 1985-12-04

Publications (1)

Publication Number Publication Date
ATE138100T1 true ATE138100T1 (de) 1996-06-15

Family

ID=27103546

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85309454T ATE138100T1 (de) 1984-12-24 1985-12-23 Fusionen von aids-verwandten polypeptiden

Country Status (6)

Country Link
EP (1) EP0187041B1 (de)
AT (1) ATE138100T1 (de)
AU (1) AU600658B2 (de)
CA (1) CA1341476C (de)
DE (1) DE3588134T2 (de)
MY (1) MY102030A (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4716102A (en) * 1984-08-15 1987-12-29 Regents Of The University Of California Purified AIDS-associated virus ARV-2
US9328391B1 (en) 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
DE3588248T2 (de) 1984-10-18 2004-07-01 Institut Pasteur LAV-Antigene und -Peptide
US7273695B1 (en) 1984-10-31 2007-09-25 Novartis Vaccines And Diagnostics, Inc. HIV immunoassays using synthetic envelope polypeptides
US7393949B1 (en) * 1987-12-24 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Human immunodeficiency virus (HIV) nucleotide sequences
CA1341482C (en) 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
US7285271B1 (en) 1984-10-31 2007-10-23 Novartis Vaccines And Diagnostics, Inc. Antigenic composition comprising an HIV gag or env polypeptide
US5008182A (en) * 1986-01-10 1991-04-16 Cetus Corporation Detection of AIDS associated virus by polymerase chain reaction
US5176995A (en) * 1985-03-28 1993-01-05 Hoffmann-La Roche Inc. Detection of viruses by amplification and hybridization
IE64785B1 (en) * 1985-04-08 1995-09-06 Genetic Systems Corp Expression of immunologically reactive viral proteins
WO1986006099A1 (en) * 1985-04-08 1986-10-23 Genetic Systems Corporation EXPRESSION AND DIAGNOSTIC USE OF gag ENCODED PEPTIDES WHICH ARE IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES TO LAV
JP2869063B2 (ja) * 1985-04-08 1999-03-10 ジエネテイツク システムズ コ−ポレイシヨン LAVに対する抗体と免疫的に反応性であるgagによりコードされたペプチドの発現及び使用
US5773210A (en) * 1985-04-19 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services Acquired immune deficiency syndrome (AIDS) viral envelope protein and method of testing for AIDS
FI861626A (fi) * 1985-04-19 1986-10-20 Hoffmann La Roche Foervaervat immunbristsyndrom (aids) -relaterat viralt rekombinant hoeljeprotein samt ett testfoerfarande foer aids.
FR2593519B1 (fr) * 1985-09-25 1994-01-07 Oncogen Vaccin contre le syndrome immunodeficitaire acquis et intermediaires pour la preparation de ce vaccin
NZ217645A (en) * 1985-09-25 1991-11-26 Oncogen Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
GB8525615D0 (en) * 1985-10-17 1985-11-20 Hoffmann La Roche Polypeptides
WO1987002775A1 (en) * 1985-10-24 1987-05-07 Southwest Foundation For Biomedical Research Synthetic peptides and use for diagnosis and vaccination for aids and arc
EP0245459B1 (de) * 1985-11-07 1993-09-29 The President And Fellows Of Harvard College T-zellen-lymphotrophisches virus-protein und testverfahren
US5068174A (en) * 1985-11-07 1991-11-26 President And Fellows Of Harvard College T-cell lymphotrophic virus protein and assay
DE3674555D1 (de) * 1985-12-20 1990-10-31 Abbott Lab Immuntest fuer antikoerper gegen htlv-iii.
NO870027L (no) * 1986-01-06 1987-07-07 Hoffmann La Roche Ekspresjon av htlv-iii gag-gen.
US5364933A (en) 1986-03-03 1994-11-15 Institut Pasteur Methods of immunopurification of antigens of human immunodeficiency virus type 2 (HIV-2)
US4839288A (en) * 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US6514691B1 (en) 1986-01-22 2003-02-04 Institut Pasteur Peptides of human immunodeficiency virus type 2 (HIV-2), antibodies against peptides of HIV-2, and methods and kits for detecting HIV-2
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4753873A (en) * 1986-02-03 1988-06-28 Cambridge Bioscience Corporation Peptides for the diagnosis of HTLV-III antibodies, their preparation and use
FR2625100A2 (fr) * 1986-03-13 1989-06-30 Lurhuma Zirimwabagabo Utilisation d'antigenes pour la preparation de vaccins, proteine rendue immunogene et composition pharmaceutique la comportant
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
US5604114A (en) * 1986-05-20 1997-02-18 Dana-Farber Cancer Institute Cis-acting repression sequences, cis-acting antirepression sequences, vectors, methods of preparation and use
US4943627A (en) * 1986-06-12 1990-07-24 Biogen, Inc. Peptides involved in the pathogenesis of HIV infection
US5017688A (en) * 1986-06-12 1991-05-21 Biogen, Inc. Peptides involved in the pathogenesis of HIV infection
EP0525828A3 (en) * 1986-08-01 1993-02-24 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
US5079351A (en) * 1986-11-26 1992-01-07 Cetus Corporation Oligonucleotides and kits for detection of htlvi and htlvii viruses by hybridization
FR2610632B1 (fr) * 1987-02-11 1990-12-21 Pasteur Institut Peptides caracteristiques des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
WO1988005440A1 (fr) * 1987-01-16 1988-07-28 Institut Pasteur Peptides ayant des proprietes immunologiques 2-hiv-2
DE3855869T2 (de) 1987-02-20 1997-10-02 Genentech Inc Verfahren und Zubereitungen für die Verwendung von HIV-env-Polypeptiden und Antikörpern
AU1334588A (en) * 1987-03-23 1988-09-22 Ortho Pharmaceutical Corporation Assay for detecting hepatitis antigens and aids antibodies
ATE126534T1 (de) * 1987-05-29 1995-09-15 Dana Farber Cancer Inst Inc Cis-wirkung-repressionen-sequenzen, cis-wirkung- antirepressionen-sequenzen, vektoren, verfahren zur vorbereitung und anwendung.
AU620330B2 (en) * 1987-05-29 1992-02-20 Smithkline Beckman Corporation Immunodiagnostic assays using chimeric antigens
IL86675A (en) * 1987-06-10 1993-04-04 Immune Response Corp Inc Immunogen containing non- infectious hiv particles and pharmaceutical compositions containing the same
US5256767A (en) * 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
DE3727137A1 (de) * 1987-08-14 1989-02-23 Behringwerke Ag Herstellung von antigenen des human immunodeficiency virus typ 1 sowie deren verwendung als diagnostisches mittel und therapeutikum
IL87391A0 (en) * 1987-08-27 1989-01-31 Repligen Corp Hiv proteins and peptides,dna coding therefor,vectors comprising such dna,the use of the proteins and peptides in diagnosis of aids and vaccine compositions containing them
EP0307149B1 (de) * 1987-09-04 1993-01-07 International Murex Technologies Corporation Festphasenimmunoassay für einen Antikörper und hierbei verwendete biologische Produkte
FR2629460B1 (fr) * 1988-04-01 1990-12-21 Pasteur Institut Peptides pf16 d'un retrovirus hiv - procede de synthese de ces peptides - leur utilisation pour le diagnostic
FR2629459B1 (fr) * 1988-04-01 1990-12-21 Pasteur Institut Peptides pf11 a pf19 d'un retrovirus hiv - procede de synthese de ces peptides - leur utilisation notamment pour le diagnostic
EP0349354A1 (de) * 1988-04-01 1990-01-03 Institut Pasteur Peptide PF10 bis PF19 von einem Retrovirus HIV, Verfahren zur Synthese dieser Peptide und ihre Verwendung, insbesondere zur Diagnose
US5204259A (en) * 1988-05-06 1993-04-20 Pharmacia Genetic Engineering, Inc. Methods and systems for producing HIV antigens
DE68917520T2 (de) * 1988-05-06 1995-01-05 Ferropas Ag Verfahren und Systeme zur Herstellung von HIV-Antigenen.
EP0434713B1 (de) * 1988-09-13 1994-10-12 Chiron Corporation Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
DE68921034D1 (de) * 1988-09-27 1995-03-23 Dana Farber Cancer Inst Inc Vektor, der ein replikationskompetentes HIV-I-Provirus und ein heterologes Gen enthält.
CA2003383A1 (en) * 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
EP0527760B1 (de) * 1990-04-03 1995-07-19 Genentech, Inc. Methoden und zusammensetzungen zur impfung gegen hiv
US7041293B1 (en) 1990-04-03 2006-05-09 Genentech, Inc. HIV env antibodies
US6316182B1 (en) * 1992-01-15 2001-11-13 Nen Life Science Products, Inc. Detection of reverse transcriptase by DNA hybridization assay
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5864027A (en) * 1993-06-07 1999-01-26 Genentech, Inc. HIV envelope polypeptides
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
US6585979B1 (en) 1996-07-08 2003-07-01 Genentech, Inc. HIV envelope polypeptides and immunogenic composition
ZA975889B (en) * 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
DE19723463A1 (de) * 1997-06-04 1998-12-10 Dade Behring Marburg Gmbh Immunchemische Bestimmung von multivalenten Analyten
ES2299276T3 (es) 1998-12-31 2008-05-16 Novartis Vaccines And Diagnostics, Inc. Polipeptidos env del vih modificados.
EP1141314A2 (de) 1998-12-31 2001-10-10 Chiron Corporation Für antigene polypeptide des hiv type c kodierende polynukleotide, entsprechende polypeptide und verwendungen davon
EP1141313A2 (de) 1998-12-31 2001-10-10 Chiron Corporation Verbesserte exprimierung von hiv polypeptiden und herstellung von virusähnliche partikeln
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
AU2002316578A1 (en) 2001-08-31 2003-03-18 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
CN106434833A (zh) 2004-05-23 2017-02-22 杰勒德·M·豪斯 Theramutein调节剂
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
CA1247005A (en) * 1984-04-23 1988-12-20 Robert C. Gallo Isolation of protein of htlv-iii, serological detection of antibodies to htlv-iii in sera of patients with aids and pre-aids conditions, and detection of htlv-iii infection by immuno-assays using htlv-iii and its proteins
IL76082A (en) * 1984-08-22 1991-07-18 Us Health Molecular clones of the genome of htlv-iii and a process for the preparation thereof

Also Published As

Publication number Publication date
MY102030A (en) 1992-02-29
EP0187041B1 (de) 1996-05-15
EP0187041A1 (de) 1986-07-09
CA1341476C (en) 2005-03-15
DE3588134D1 (de) 1997-01-23
AU600658B2 (en) 1990-08-23
AU5170585A (en) 1986-10-16
DE3588134T2 (de) 1997-03-20

Similar Documents

Publication Publication Date Title
ATE138100T1 (de) Fusionen von aids-verwandten polypeptiden
DK84194A (da) Rekombinant hepatitis B-virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenetiske polypeptider, DNA-sekvenser kodende herfor, fremgangsmåder til påvisning af hepatitis B-virus antistoffer i blodserum, fremgangsmåder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider, midler til påvisn
DE3588252D1 (de) Rekombinante Proteine von mit Lymphadenopathiesyndrom und/oder erworbenem Immunschwächesyndrom assoziierten Viren
ATE98992T1 (de) Klonierung und expression von htlv-iii dns.
ATE229543T1 (de) Polypeptide des hepatitis c-virus (hiv)
DK626486D0 (da) Syntetiske antigener til afslaering af aids-relateret sygdom
ES8700441A1 (es) Metodo de diagnostico de enfermedades y perfeccionamientos en los sistemas de ensayo de sueros
DE69534569D1 (de) Hiv-1- und hiv-2-peptide zur hemmung von mit membranfusionen in zusammenhang stehenden phänomenen, einschliesslich der übertragung von hiv
SE9102976L (sv) Hybrid dna vektorer, encelliga organismer och bakterier till anvaendning foer produktion av hiv-proteiner och peptider
NO173958C (no) Fremgangsmaate for paavisning av tilstedevaerelse av antistoff mot HIV-virus
ATE172542T1 (de) Vergrössertes western blot format und ein immunotestverfahren für die bestimmung von viralen antikörpern
DE3650019D1 (de) Expression von Virusproteinen mit immunologischer Aktivität.
ATE420183T1 (de) Antigen-konstrukte, für den nachweis und die unterscheidung von antikörpern gegen hiv
ATE87487T1 (de) Rekombinante hiv-2 polypeptide.
DE3850593T3 (de) Synthetische Antigene zur Bestimmung der AIDS-bezogenen, von LAV-2 verursachten Krankheiten.
ATE72459T1 (de) Herstellung von einschlussproteinfragmenten von menschlichem t-zellen-leukemia-(lymphotropischem)-retrovirus (htlv-1) in bakterien und verwendung fuer die seroloimologische pruefung von menschlicher lymphoid-malignitaet.
DE69028561T2 (de) Immunoassay zum Nachweis von Antikörpern gegen HIV
EP0270114A3 (de) ENV/GAG-Polypeptide
DE68917520T2 (de) Verfahren und Systeme zur Herstellung von HIV-Antigenen.
Lenz et al. Serologische AIDS-Diagnostik mit gentechnisch gewonnenen Polypeptiden des menschlichen Immundefizienz-Virus (HIV-1)
Azocar et al. Lack of endemic HIV infection in Venezuela
Neumuller DNA polymerase activity assays: New techniques and applications in tumor and viral diseases, notably HIV infection.
ES2155436T3 (es) Proteinas recombinantes con la reactividad inmunologica del antigeno e del virus de la hepatitis b (hbeag), procedimiento para su preparacion y su utilizacion en analisis inmunologicos y en vacunas.
NO881501L (no) Rekombinante htlv-111-proteiner og anvendelser av disse.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time